Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Livforsakringsbolaget Skandia Omsesidigt

Livforsakringsbolaget Skandia Omsesidigt increased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 22,065 shares of the pharmaceutical company’s stock after acquiring an additional 258 shares during the period. Vertex Pharmaceuticals makes up 0.9% of Livforsakringsbolaget Skandia Omsesidigt’s portfolio, making the stock its 23rd biggest position. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Vertex Pharmaceuticals were worth $8,978,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of VRTX. Venturi Wealth Management LLC lifted its position in shares of Vertex Pharmaceuticals by 1.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,293 shares of the pharmaceutical company’s stock worth $933,000 after purchasing an additional 24 shares in the last quarter. Arthur M. Cohen & Associates LLC lifted its position in shares of Vertex Pharmaceuticals by 3.2% in the fourth quarter. Arthur M. Cohen & Associates LLC now owns 800 shares of the pharmaceutical company’s stock worth $326,000 after purchasing an additional 25 shares in the last quarter. Baystate Wealth Management LLC lifted its position in shares of Vertex Pharmaceuticals by 49.0% in the fourth quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock worth $31,000 after purchasing an additional 25 shares in the last quarter. Cooper Financial Group lifted its position in shares of Vertex Pharmaceuticals by 1.0% in the third quarter. Cooper Financial Group now owns 3,020 shares of the pharmaceutical company’s stock worth $1,050,000 after purchasing an additional 29 shares in the last quarter. Finally, Arjuna Capital lifted its position in shares of Vertex Pharmaceuticals by 0.7% in the third quarter. Arjuna Capital now owns 4,375 shares of the pharmaceutical company’s stock worth $1,521,000 after purchasing an additional 29 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX traded down $1.07 on Wednesday, hitting $393.10. The stock had a trading volume of 880,342 shares, compared to its average volume of 1,249,131. Vertex Pharmaceuticals Incorporated has a twelve month low of $316.43 and a twelve month high of $448.40. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99. The firm’s 50 day moving average price is $415.28 and its 200-day moving average price is $396.78. The company has a market capitalization of $101.60 billion, a price-to-earnings ratio of 28.30, a price-to-earnings-growth ratio of 1.87 and a beta of 0.35.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 EPS for the quarter, beating the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The company had revenue of $2.52 billion for the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter in the previous year, the company earned $3.33 EPS. On average, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current year.

Insider Activity

In other news, EVP Amit Sachdev sold 3,222 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,354,013.28. Following the sale, the executive vice president now owns 74,364 shares in the company, valued at approximately $31,250,727.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Amit Sachdev sold 3,222 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,354,013.28. Following the completion of the transaction, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at $31,250,727.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Stuart A. Arbuckle sold 4,295 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,804,930.80. Following the completion of the transaction, the chief operating officer now directly owns 75,718 shares of the company’s stock, valued at $31,819,732.32. The disclosure for this sale can be found here. In the last quarter, insiders have sold 12,381 shares of company stock worth $5,203,249. Corporate insiders own 0.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on VRTX. Sanford C. Bernstein lowered shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Friday, February 2nd. HC Wainwright raised their price objective on shares of Vertex Pharmaceuticals from $457.00 to $462.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Royal Bank of Canada raised their price objective on shares of Vertex Pharmaceuticals from $397.00 to $420.00 and gave the company a “sector perform” rating in a research report on Tuesday, February 6th. Canaccord Genuity Group reissued a “sell” rating and issued a $371.00 price target on shares of Vertex Pharmaceuticals in a research report on Friday, April 12th. Finally, Robert W. Baird lowered shares of Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 price target on the stock. in a research report on Wednesday, January 31st. Three research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $424.62.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.